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1. Introduction 
Posttransplant lymphoproliferative disorder (PTLD) is a rare but life threatening disorder 
following both solid organ and hematopoietic stem cell transplantation. The disorder is 
characterized by an uncontrolled proliferation of lymphocytes, caused by medication 
induced diminished immune surveillance. From a pathological point of view PTLD has a 
broad and heterogeneous spectrum of appearance, ranging from a benign condition to frank 
lymphoma. Although not required for diagnosis of PTLD, Epstein Barr virus (EBV) plays a 
major role in the pathogenesis of the majority of PTLDs. Currently the gold standard in 
diagnosis of PTLD remains biopsy with histopathologic examination to categorize every 
case according to the World Health Organization 2008 classification. Similar to its 
heterogeneous presentation treatment options are diverse and may include preventive, 
preemptive, curative and palliative approaches. However, the backbone of all PTLD 
therapies –except maybe for real palliation- should be (partial) reconstitution of the immune 
system. 
2. Posttransplant malignancies 
Historically long term follow up of solid organ recipients was limited by low graft and 
patient survival, mainly due to rejection and infectious complications. However, due to 
improvement in care and cure of these problems, as well as permitting increased donor and 
recipient age, posttransplant malignancies and cardiovascular disorders have emerged as 
the most important long term complications. The incidence of malignancies in solid organ 
transplant patients is estimated to be 20% following 10 year of chronic immunosuppression.1 
Skin cancer and lymphoproliferative disorders are the two most frequent malignancies in 
this specific patient population. Besides these two malignancies transplant patients are 
vulnerable to many other neoplasms.2 These can occur de novo,  can be a consequence of the 
underlying condition leading to transplantation or –in rare cases- can be transmitted by the 
donor.3 Screening, early detection and staging have become an essential part of 
posttransplant management, given the good prognosis associated with in situ or low grade 
malignancies. Besides classical prevention including nicotine withdrawal and ultraviolet 
protection is essential.1    
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3. Incidence 
The incidence of PTLD varies according to the type of organ transplanted. Compared to 
heart, lung and intestinal transplantation, incidence of PTLD in kidney transplant recipients 
is relatively low and is estimated to be 1-1.5%.4 However, due to the high kidney transplant 
activities, the absolute number of PTLD is probably the highest in kidney transplant 
recipients. Lacking large prospective trials, retrospective single center studies and registry 
databases have been the major source of information in collecting epidemiology, incidence, 
(patient, disease and treatment related) characteristics and outcome data on PTLD. The main 
advantage of single center retrospective analyses is the provision of more detailed 
information (for example EBV status, specific information on immunosuppressive 
regimens,…), although the number of included patients is rather small. Transplant registries 
on the other hand provide information on a larger number of patients, but this information 
is mostly very limited and depends on the goodwill and the correct registration of the 
physicians and transplant coordinators. Information from large population based cohort 
studies indicate that standardized incidence ratios (SIR), reflecting the ratio between 
observed and expected cases, in solid organ recipients approach 10 in non Hodgkin 
lymphoma and 3.5 in Hodgkin lymphoma.5,6 Initially the highest incidence was reported in 
the first year following transplantation (‘early onset PTLD’), although currently ‘late onset 
PTLD’ is diagnosed more frequently, probably due to the improved survival of transplant 
patients and to increased awareness. Because of the above described limitations of registries 
incidence data are best derived from small single center series. However it seems that 
complete and standardized nationwide prospective data registry is mandatory to permit 
more precise estimates on incidence of PTLD in the transplant population.    
4. Risk factors 
Risk factors associated with occurrence of PTLD following SOT are multiple, as shown in 
table 1.  
 
EBV status at time of transplantation (donor negative/recipient positive) 
Type of transplanted organ  
Intensity/duration of immunosuppressive therapy  
Underlying disorder  
Infectious agents other than EBV (CMV?, HCV?, ...) 
Age of donor and recipient  
Number and severity of rejection episodes  
Cytokine gene polymorphisms  
HLA alleles/haplotypes/mismatches/antibodies  
Table 1. Risk factors for development of PTLD 
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4.1 EBV mismatch 
The most important independent risk factor is pre-transplantation EBV mismatch (recipient 
seronegative/donor seropositive), leading to a 10-75 times greater incidence of PTLD 
compared to EBV seropositive recipients. As EBV seroconversion positively correlates with 
increasing age, the higher incidence of EBV mismatch in pediatric transplant procedures 
may explain the higher incidence of PTLD in childhood.7  Although transplant patients with 
EBV mismatch are especially prone to occurrence of early PTLD8, EBV seronegativity 
remains a risk factor after one year following transplantation.9   
4.2 Type of organ transplantation  
As already mentioned before, another major risk factor comprises the type of transplanted 
organ. Incidence of PTLD is highest in heart-lung and multivisceral transplantation (up to 
20%),  followed by liver (4.5%), heart and lung (2.5%), pancreas (2%), kidney (1-1.5%) and 
finally matched related and unrelated hematopoietic stem cell transplantation (0.5-1%).4  In 
a retrospective analysis of the Collaborative Transplant Study (CTS) database relative risk 
(RR) was highest in heart-lung transplantation (RR 239.5) and lowest in kidney transplant 
recipients (RR 12.6).10 The reason for these differences are largely unknown. Possible 
hypotheses include the fact that high risk transplantations require more profound  
immunosuppression and contain  large amounts of lymphoid tissue, leading to increased 
risk for EBV infection.4   
4.3 Immunosuppressive regimen      
A third important risk factor is the use of potent and prolonged immunosuppressive 
medication used to prevent or treat graft rejection. Taken together the risk for developing 
PTLD seems to be correlated with the cumulative intensity of immune suppression, leading 
to decreased viral and malignant surveillance. In this way repeated episodes of acute 
rejection increase the risk of PTLD.2 However, measuring the cumulative 
immunosuppressive intensity is not easy. Firstly, transplant protocols almost always use 
combination therapy, making the determination of each drug separately very difficult. 
Secondly, registration of dose modifications/interruptions during the posttransplant period 
requires a major effort and consequently registration of these activities is very poor. Thirdly, 
besides maintenance therapy induction and repeated episodes of anti-rejection therapies 
might influence the risk of PTLD. Finally, no single laboratory test exists measuring the total 
amount of immunosuppression in a patient.11  Due to these difficulties in determining the 
overall role of immunosuppression, interest has largely shifted to identification of the role of 
specific immunosuppressive medication.  
4.3.1 Calcineurin inhibitors 
Currently data on a possibly increased risk of calcineurin inhibitors (CNI) are very 
controversial. Although structurally unrelated to cyclosporine A, tacrolimus’ mechanism of 
action is similar with inhibition of calcineurin and subsequent of  Interleukin 2-production 
being the common pathway.12  However, the immunosuppressive activity of tacrolimus 
seems to be stronger compared with cyclosporine A, leading to improved kidney graft 
survival and prevention of rejection at 1 year.13 These stronger immunosuppressive 
properties seem to be translated in a higher risk for development of PTLD. In their CTS 
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database Opelz et al found a statistical significant increased cumulative incidence of PTLD 
in patients receiving combination therapy with tacrolimus and mycophenolate mofetil 
(MMF) or azathioprine compared with patients on cyclosporin A and MMF or 
azathioprine.10  This increased risk of tacrolimus compared to cyclosporin A was confirmed 
in a United States cohort of kidney recipients, but only in case no induction therapy was 
given14, and in a Organ Procurement and Transplant Network/United Network for Organ 
Sharing (OPTN/UNOS) registry study, though the difference didn’t reach statistical 
significance in this last trial.15  On the other hand Pirsch et al didn’t find a difference in 
PTLD incidence in a prospective randomized study comparing both CNI following kidney 
transplantation. However, as the follow up in this study was only one year no real 
conclusions can be made.16   An important characteristic of CNI is their ability to enhance 
production of transforming growth factor ┚1 (TGF┚-1). Together with the finding that 
cyclosporin A can cause impaired DNA repair, a direct oncogenic effect might contribute to 
the occurrence of malignancies in patients treated with CNI.17-19    
4.3.2 Antimetabolites 
Azathioprine is a purine analogue which is, following metabolisation and conversion to 
different compounds, incorporated into replicating DNA.20  In prevention of renal graft 
rejection it is largely replaced by MMF, which has been proven to be more effective than 
azathioprine in the prevention of allograft rejection.21  MMF is converted in the liver to its 
active compound mycophenolic acid, which blocks inosine monophosphate dehydrogenase, 
disturbing DNA synthesis.20 Azathioprine has well known synergism with ultraviolet 
radiation in carcinogenesis, leading to increased risk of skin cancers.22 Besides the drug also 
induces mutagenesis due to DNA mismatch repair deficiencies, explaining also the 
observed increase of therapy related acute myeloid leukemia/myelodysplastic syndrome.23  
In contrast to azathioprine, several studies have shown that MMF is not associated with an 
increased risk24,25  and even with a reduction in the number of PTLDs following kidney 
transplantation.14,26 However, in the CTS report incidence of PTLD was similar irrespective 
of the use of azathioprine versus MMF.10  As already discussed above combination with 
tacrolimus was associated with an increased risk compared to combination with cyclosporin 
A.10  
4.3.3 Mammalian target of rapamycin inhibitors 
Mammalian target of rapamycin (mTOR) inhibitors display their activity by blocking the 
serine-threonine kinase mTOR.27 Currently two of these proliferation signaling inhibitors 
(PSI) are used in organ transplantation, namely sirolimus and everolimus. Apart from its 
immunosuppressive properties, mTOR inhibitors also possess antiproliferative 
characteristics, making their use very attractive especially in high risk patients and in CNI-
free regimens.28-30 However, in a recent retrospective study in kidney transplant patients 
maintenance therapy was associated with higher PTLD incidence.31 In addition Mathew et 
al performed a multicenter analysis of renal transplant patients receiving sirolimus as base 
therapy or as maintenance. Although the two-year incidence of malignancies, especially skin 
cancer, was significantly lower, the risk of developing PTLD was increased in comparison 
with classical immunosuppressive therapy, especially when high dose sirolimus (5 mg/day) 
was given.32    
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4.3.4 Polyclonal T cell depleting antibodies 
Initially used in the treatment of acute rejection following organ transplantation and of 
graft-versus-host disease after bone marrow transplantation, the use of anti-lymphocyte and 
anti-thymocyte globulins (ALG/ATG) has shifted to the prevention of both severe 
complications of transplantation. These antibodies bind to different antigens, not only on T 
cells but also on most other immunological players, although exact mechanism of action has 
not been fully understood yet.33 The use of ATG was found to increase the risk for PTLD in 
hematopoietic stem cell transplantation34, however its role in solid organ transplantation is 
less well established. In most registry studies there is a clear association between the use of 
ATG and the occurrence of PTLD.10,14,31 On the other hand Hardinger et al recently 
published the results of a small but prospective, randomized, double-blind study in kidney 
transplant recipients comparing induction therapy with rabbitATG (Thymoglobulin) and 
horseATG (ATGAM). With 10 years follow up the composite primary endpoint of  freedom 
from death, graft loss or acute rejection was significant higher in the Thymoglobulin-group. 
Importantly no patients in the Thymoglobulin group (n=48) and two in the ATGAM group 
(n=24) were diagnosed with PTLD.35  In another registry study Dharnidharka et al found an 
increased risk in kidney transplant recipients treated with horseATG, but not with 
rabbitATG, although the follow up in the latter group was significantly shorter.36  
4.3.5 Monoclonal T cell depleting and non-depleting antibodies 
Muromonab CD3 (= OKT3) is a murine monoclonal antibody directed against the CD3 
antigen on the surface of human T cells.37  In their CTS study Opelz et al reported a higher 
incidence of early PTLD in patients receiving induction therapy with OKT3 or ATG.10 
However, other studies failed to show an association between OKT3 induction and PTLD.37 
Mainly due to xenosensitisation, pulmonary toxicity and to its relationship with 
malignancies, its use has been largely replaced by polyclonal or other monoclonal 
depleting/non-depleting antibodies. 
Alemtuzumab is a humanized rat monoclonal antibody directed against the CD52 antigen. 
This antigen is expressed on the surface of peripheral blood lymphocytes, natural killer cells, 
monocytes and macrophages.38 Because of the depletion of both B- and T-cells alemtuzumab 
possesses a theoretical advantage of reduced B cell mass and hence protection against (EBV 
related) B cell proliferation. Although data on the association between alemtuzumab 
induction and PTLD in kidney transplant recipients are limited, there seems to be no 
association.39,40 This was confirmed in a UNOS registry study comparing no induction,  
depleting and non-depleting induction therapy.31    
Based on decreased acute rejection rates anti-interleukin-2 receptor (CD25) monoclonal 
antibodies have emerged as an important part of immunosuppressive regimens in kidney 
transplant recipients due to selective depletion of activated T cells. Basiliximab is  a chimeric 
antibody, whereas daclizumab is humanized.41  In a study using data from the Scientific 
Registry of Transplant Recipients Bustami et al found a significant increased adjusted 
relative risk for PTLD using basiliximab or daclizumab.42 However, other registry studies 
failed to find an association between anti-CD25 induction therapy and risk for PTLD, 
leading to the general assumption that basiliximab and daclizumab do not increase the risk 
for PTLD.10  Magliocca et al retrospectively compared induction therapy with alemtuzumab 
and basiliximab in combined pancreas-kidney transplantation, but found no difference of 
PTLD occurrence in the first two years following transplantation.43  
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4.3.6 Co-stimulation blockade. 
For their activation, T cells require two signals. Signal 1 represents interaction between the T 
cell receptor (TCR) and major histocompatibility (MHC) complex on an antigen presenting 
cell (APC). Co-stimulation signaling (signal 2), also achieved by interactions between APCs 
and T-cells, is obligatory  for complete activation of the T cell. In the absence of this signal, T 
cells will fail to proliferate and will finally become apoptotic or anergic. Of these signal 2 
interactions, those between B7 (CD80 and CD86)  and CD40 [APC] and CD28 and CD40L 
(CD154) [T cells] respectively seem to be the most important for T cell activation. After  
CD28 has delivered  a signal for T cell activation,  CTLA4 (cytotoxic T-lymphocyte-
associated antigen 4) is transiently upregulated on T cells. This molecule  is a negative 
regulator of T-cell activation by inhibiting binding of CD28 to CD80 and CD86, due to its 
higher affinity compared with CD28.44    
Inhibiting of this co-stimulation signal has become a promising approach in both 
autoimmune disorders and transplantation, leading to two phase III trials (BENEFIT and 
BENEFIT-EXTENT) comparing the selective co-stimulation blocker belatacept and 
cyclosporin A in kidney transplant recipients. Belatacept is a human fusion protein 
combining the extracellulair domain of CTLA4 with the constant-region fragment (Fc) of 
human IgG1. In both trials patients treated with betalacept-containing immunosuppression 
had an increased incidence of PTLD. Interestingly, in the BENEFIT-EXTENT study 4 of 5 
PTLD cases showed central nervous system involvement. Risk factors for PTLD included 
EBV seronegativity pre-transplantation and the use of a more intensive regimen of 
belatacept.45,46  The former finding has led to the recommendation to abandon the use of 
belatacept in patients with a seronegative EBV status before transplantation.47 In another 
phase I/II trial with efalizumab, targeting  CD11a, the alpha subunit of lymphocyte 
function-associated antigen-1 (LFA-1),  3 out of 38 kidney transplant recipients receiving 
combination therapy with high doses efalizumab and cyclosporine A were diagnosed with 
PTLD.48 
In summary we can conclude that currently no firm conclusion can be made for individual 
contribution of these different drug classes with respect to the risk for PTLD, although use  
of monoclonal anti-CD3, polyclonal anti-thymocyte antibodies (ATG) and possibly some 
new and potent agents seem to be associated with an increased risk in most studies, whereas 
mycophenolate mofetil, monoclonal anti-CD52 and anti-IL2-R-antagonists probably are not. 
However, taking into account the increasing number of late onset PTLD, cumulative 
intensity seems to influence the risk mostly.   
4.4 Other risk factors 
Many other risk factors have been described and proposed. However their exact 
relationship with development of PTLD is less established in comparison to the above 
discussed factors.  
Although the role of patient related risk factors including age, gender and race have been 
described, literature results are too conflicting to draw any conclusion at this moment.   
Underlying immunodeficiency disorders, especially primary immune deficiency (PID) and 
autoimmune hepatitis leading to hematopoietic stem cell and liver transplantation 
respectively, seem to be associated with increased risk for development of PTLD.49,50 The 
main reason for this probably is the prolonged (disease or treatment related) pre-
www.intechopen.com
 Posttransplant Lymphoproliferative Disorders Following Kidney Transplantation 
 
85 
transplantation immune compromised situation. In renal transplantation no such 
association has been found. Whether end stage renal disease (ESRD) and subsequent need 
for renal replacement therapy (RRT) contribute to the PTLD risk following kidney 
transplantation was investigated in a large population based Australian cohort study, 
comparing cancer SIRs for patients with ESRD before RRT, patients on RRT and transplant 
patients. Because SIRs for most cancers, in particular lymphoproliferative disorders, were 
not increased in the ESRD and RRT groups, the risk of PTLD seems to be associated mainly 
by the iatrogenic immunosuppression posttransplant.5  
About 80-85% of the PTLD cases are associated with EBV primary infection or reactivation    
(described in ‘Pathogenesis’).4  The pathogenesis of the remaining 15-20% is less clear. These 
EBV negative cases have the tendency to occur late following transplantation. Possible 
explanations include involvement of other infectious agents or loss of EBV during PTLD 
evolution (‘hit and run’ hypothesis).51 This hypothesis is supported by the description of 
Burkitt and Hodgkin lymphoma cases who seem to lack expression of EBV genes, but still 
have fragments of EBV DNA.52  Different viruses have been identified as important 
contributors of lymphomagenesis, both in immunocompetent and immunosuppressed 
patients. Although Hezode et al reported on a possible higher incidence of PTLD in liver 
transplant patients with underlying hepatitis C cirrhosis53, this finding could not be 
confirmed in a recently published large cohort study in solid organ transplant recipients.54 
Cytomegalovirus (CMV) is another virus which has been suggested as potentially PTLD-
inducing virus in some single center studies, yet the number of cases are very small and 
currently there is no hard evidence to support its role in PTLD.55-57 
Despite different cohorts of patients receive a similar cumulative intensity of 
immunosuppression, only a minority of patients will develop PTLD, pointing to a possible 
role of genetic susceptibility. In this way different authors have shown an increased risk for 
PTLD associated with cytokine gene and cytokine receptor gene polymorphisms including 
Tumor Necrosis Factor-┙, Interferon-┛, Interleukin-10 and Transforming Growth Factor-┚.58-
60 Although the use of these molecular techniques currently is not applicable in daily 
practice, they might become useful in predicting the risk for PTLD. However, recent data on 
some previously described predictive cytokine receptor gene polymorphisms were not able 
to confirm these findings.61      
Given the important role of the Human Leucocyte Antigen (HLA)-system in transplantation 
immunology, its predictive role in development of PTLD has been suggested. Most evidence 
has derived from small patient populations with isolated, but not confirmed findings 
supporting the contribution of specific donor/patient HLA alleles, HLA haplotypes, HLA 
mismatches and pre-existing HLA-antibodies in the development of PTLD in transplant 
recipients.62-64  Clearly, larger studies are needed to further clarify this complex association. 
5. Pathogenesis 
The pathogenesis and biology of PTLD is complex and multifactorial, as reflected by the large 
heterogeneity in time of occurrence and clinical and pathological presentation. In the majority  
(80-85%) of cases onset of PTLD is Epstein Barr virus (EBV) driven, leading to uncontrolled B-
cell proliferation due to deficient cellular immune response. EBV is a herpesvirus, infecting 
more than 90% of the world population worldwide. Following primary infection, the virus 
persists in the host during the whole life mostly  without harmful effects. However, EBV has 
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the capacity to transform B cells, resulting in different lymphoproliferative disorders, in 
particular Burkitt non Hodgkin lymphoma, Hodgkin lymphoma and PTLD.65  
The pattern of different viral gene expression used by EBV is called the growth program. 
These genes encode for different functional homologues of B-cell factors involved in cell 
cycle regulation, inhibition of apoptosis and signal transduction.65 In this way EBV is able to 
use the normal B cell program and promote proliferation and transformation of these cells.66  
In healthy persons EBV is kept in a silent state in memory B cells without expressing any 
viral protein, corresponding with latency program (type 0). Based on the gene expression of 
different EBV-encoded genes, other growth programs can be seen (table 2). In Burkitt 
lymphoma the majority of EBV positive cases show a highly restricted latency I program of 
infection (Epstein Barr nuclear antigen-1 =  EBNA-1 only program), whereas EBV positive 
Hodgkin lymphoma is characterized by a type II latency (default) program. 
Lymphoproliferative disorders occurring in immunosuppressed patients (PTLD and some 
HIV related lymphomas) most often express the latency III  (growth) program, although  
other gene expression patterns have been described in PTLD.65,67  Latency III program is 
critical for B cell activation and transformation, which becomes uncontrolled if not inhibited 
by cytotoxic T cell activity.68 This explains why reduction of immune suppression, leading to 
(partial) restoration of immune control, is considered the first and most important 
therapeutic intervention, especially in early (EBV positive) PTLD cases.   
 
Transcription program EBV genes expressed Occurrence 
Type 0 (latency) None 
Peripheral blood memory 
B cells (healthy persons) 
Type I (EBNA-1 only) EBNA-1 Burkitt NHL 
Type II (default) EBNA-1, LMP-1, LMP-2A Hodgkin lymphoma 
Type III (growth) 
EBNA-1 till -6, LMP-1, 
LMP-2A, LMP-2B 
PTLD 
Table 2. EBV transcription programs in human lymphoproliferative disorders 
Another important mechanism in the pathogenesis of PTLD is situated at the graft organ 
level. Chronic antigen stimulation of recipient B cells by donor antigens may give rise to B 
cell proliferation and PTLD in case of inadequate immune surveillance. On the other hand, 
donor lymphoid cells (especially in organ transplantation with a high lymphoid load such 
as lung, bowel and liver transplantation) may be exposed to chronic recipient derived 
antigen stimulation, leading to donor lymphoid cell proliferation in a tolerant 
environment.69 These cases of donor derived PTLD are characterized by early presentation 
and are often limited to the allograft, in contrast to the more frequent recipient derived 
PTLD occurring later and disseminated at presentation.70  
6. Symptoms 
The clinical presentation of patients with PTLD is very variable, ranging from an 
asymptomatic finding to fulminant general deterioration rapidly evolving into multi organ 
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failure. Differential diagnosis with graft rejection (in case of graft involvement) and infectious 
complications/sepsis (in case of symptomatic disseminated disease) may be very difficult. 
Children may present with painful throat, fever and adenopathies resembling an infectious 
mononucleosis-like picture with tonsilla and Waldeyer ring involvement. Besides classical 
nodal involvement with or without B symptoms, PTLD is characterized by a high incidence of 
extranodal invasion, including bone marrow and central nervous system (CNS) involvement.71 
Although initially a high incidence (15%) of primary and secondary CNS lymphoma was 
described in PTLD patients72, recent reports show incidences between 5 and 13%.73-75  
As already discussed above early PTLD may have a different presentation compared to late 
PTLD with more frequently positive EBV state and involvement of the allograft.70,76,77 
7. Diagnosis 
The gold standard in diagnosis of PTLD remains biopsy with histopathologic examination, 
although cytological preparations may also be useful, especially in case of effusion 
lymphoma. According to the current World Health Organization (WHO) PTLD is a subtype 
of ‘Immunodeficiency associated lymphoproliferative disorders’, in close correlation with 
other Primary Immune Deficiency (PID), Human Immunodeficiency Virus (HIV) and 
Methotrexate-associated lymphoproliferative disorders.78   
In addition to morphological examination of the biopsy immunohistochemical analysis with 
at least CD3 and CD20 staining to differentiate between B cell and T cell origin is necessary 
in the evaluation of suspected PTLD. Other markers, including CD15, CD30, CD38, CD138 
and MUM1 may provide additional information in case of rare subtypes. Cytogenetic and 
molecular analysis may provide important information on the monoclonal nature of the 
disorder and may help in understanding the biology of PTLD by analyzing oncogenes and 
tumor suppressor genes. Finally presence or absence of EBV should be demonstrated in all 
cases, which can be done by different techniques. EBV Early RNA (EBER) in situ 
hybridization is the preferred method as EBER transcripts are abundantly present, show 
relative stability and are expressed in all types of latency. Alternatives include 
immunoperoxidase staining for EBV Latent Membrane Protein 1 (LMP-1) or the use of 
Epstein Barr nuclear antigen-2 (EBNA-2) antibodies. However, LMP-1 and EBNA-2 are not 
expressed in all latency types, leading to false negative results.79 
Based on morphological and immunohistochemical findings the WHO distinguishes four 
major categories of PTLD, ranging from polyclonal early lesions to aggressive monoclonal 
lymphoproliferative disorders resembling the broad spectrum of typical lymphomas 
occurring in immunocompetent persons (figure 1).78 
7.1 Early lesions 
Two typical early lesions have been recognized by the WHO: plasmacytic hyperplasia and 
infectious mononucleosis-like lesions. These abnormalities are characterized by a 
preservation of the underlying architecture of the tissue involved. They typically occur early 
(within one year) following transplantation and the large immunoblasts are infected with 
EBV, as shown by EBV Early RNA (EBER) in situ hybridization or  EBV Latent Membrane 
Protein (LMP)-1 staining. These lesions are considered the first morphological changes in 
PTLD and their benign characteristics have been confirmed by the absence of oncogene or 
tumor suppressor gene mutations.   
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              A    B             C  
              D    E             F 
              G    H             I 
A-D. Early lesion, plasmacytic hyperplasia. A. H&E low power view. Preserved lymph node 
architecture. B. High power view shows numerous plasma cells. C. Plasma cells stain with 
CD138/syndecan. D. EBER in situ hybridisation shows small amount of positive cells. 
E-G. Polymorphic PTLD. E. Low power view shows disturbed lymph node architecture. F. Higher 
power shows a polymorphic infiltrate composed of plasma cells, lymphocytes (small, medium-sized, 
large and Reed-Sternberg-like). G. EBER ISH shows numerous positive cells. 
H-I. Monomorphic PTLD. H. Diffuse proliferation of large atypical cells. I. CD20 staining shows their B-
cell origin (Courtesy to Prof Thomas Tousseyn). 
Fig. 1. Morphology and immunohistochemistry of PTLD 
7.2 Polymorphic PTLD 
This subtype is characterized by a mixed lymphoproliferation consisting of a large spectrum 
of different cells like immunoblasts, mature plasma cells and intermediate sized lymphoid 
cells. Different specific features including atypia, necrosis and mitotic figures may be seen in 
the biopsy. Immunophenotyping, which has no real value in early lesions, shows a variable 
mixture of both B and T cells. In most cases this subtype is EBV related as well. In contrast to 
early lesions clonal abnormalities may be present, reflecting the transition to malignant 
transformation.  
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7.3 Monomorphic PTLD 
This subtype is characterized by architectural and cytological abnormalities which can 
impossibly be distinguished from lymphomas occurring in immunocompetent patients. 
Similar to classical lymphoproliferative disorders they can be subclassified in B-, T- and NK-
cell non Hodgkin lymphoma (NHL). Although not always present, most of the 
monomorphic PTLDs seem to be EBV driven as well. Besides the clear monoclonal 
appearance, additional mutations in oncogenes (N-Ras, c-Myc,…) and tumor suppressor 
genes (p53,…) are not uncommon.  
In the majority of cases monomorphic PTLD has a B-cell phenotype, with diffuse large B cell 
lymphoma (DLBCL) being the prototype. Although immunoblastic, centroblastic and 
anaplastic DLBCL have been described, the clinical significance of these morphological 
subtypes is not entirely clear. However, being CD20 negative, anaplastic DLBCL may confer 
a poor prognosis given the fact that anti-CD20 therapy cannot be used. Other types of B-
PTLD include Burkitt(-like) NHL, plasmablastic NHL and plasma cell myeloma, which can 
be EBV driven as well.    
In contrast to B-PTLD T/NK lymphomas are rather rare following transplantation. Most T cell 
cases do not show positive EBV staining, although EBV positive cases have been described. 
Possible explanations for this last finding include expression of CD21 or other not yet 
identified receptors leading to EBV infection. The largest series of T- and NK-PTLD, including 
130 cases, has been described by Swerdlow et al with 69% occurring after kidney 
transplantation. Different subtypes were identified including peripheral T cell lymphoma, 
unspecified (PTCL,U), hepatosplenic gamma-delta T cell lymphoma (HSGDTCL) and 
anaplastic large T cell lymphoma (ALCL). Most cases occurred late following transplantation 
and only 37% of the cases were EBV positive. The prognosis was very poor with overall 
survival of only 6 months, although EBV positive cases tended to have a better outcome.80      
7.4 Hodgkin lymphoma / Hodgkin-like lymphoma 
Although this subcategory constitutes only a very small proportion of PTLD, population based 
cohort studies have shown SIRs of 3.5 for Hodgkin lymphoma following solid organ 
transplantation5,6, with the risk being even higher after bone marrow transplantation.81  
Despite most evidence is based on case reports and smaller case series HL-PTLD is mostly 
EBV related and is associated with a better prognosis compared to other subtypes of PTLD.82,83    
Whether there is a difference between monomorphic Hodgkin lymphoma (HL) and 
polymorphic Hodgkin-like lymphoma (HLL) following transplantation is not entirely clear. 
In an overview of the literature on this topic Semakula et al described different clinical, 
immunophenotypic and molecular features of both subtypes, with HLL behaving more 
aggressively and probably requiring a NHL-therapeutic approach, whereas real HL may be 
treated in the same way as classical HL.84  
Although the WHO 2008 classification provides an important framework in correct diagnosis, 
some problems remain. Firstly, apart from these four categories other lymphoma subtypes 
have been reported following transplantation, though these have not been included in the 
current WHO classification. Aull et al  described 16 cases of marginal zone lymphoma 
following solid organ transplantation. The majority of these lymphomas showed gastric 
localization, occurred late and were associated with Helicobacter pylori positivity (and not 
EBV). Treatment of most cases included reduction of immunosuppression and helicobacter 
pylori eradication therapy, leading to excellent disease control and prognosis.85  It can be 
expected that, due to improved survival and to increasing age of transplant recipients, more 
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indolent lymphoproliferative disorders will occur in the transplant population. Whether these 
lymphomas should be considered real PTLD or only reflect an ageing population needs to be 
explored further.86 Secondly it’s important to stress that progression or recurrence of a 
lymphoproliferative disorder already existing before transplantation, does not fulfill criteria 
for PTLD.87  Finally,   it’s clear that  not all cases are easily classified in the well known 
lymphoma categories, reflected by the finding of several “grey zone lymphomas”. 
8. Staging 
Once the diagnosis of PTLD has been established staging examinations need to be 
performed in order to exactly define the extent of involvement of lymph nodes and organs, 
including the allograft itself. Staging tools are comparable to those used in classical 
lymphomas with computed tomography (CT) scan, magnetic resonance imaging (MRI) of 
the brain and bone marrow examination being of great importance. The staging system most 
used in lymphoma is the Ann Arbor Classification (table 3).88 However, as extranodal 
involvement is a frequent feature of PTLD and because CT is not able to discriminate 
between vital and non-vital tumor lesions, CT scan may not be the most appropriate staging 
tool. Besides, the use of intravenous contrast may be relatively contra-indicated in kidney 
transplant recipients with compromised renal function. These drawbacks have lead to 
emerging interest in the use of 18fluorodexyglucose- positron emission tomography (FDG-
PET) scan. FDG-PET is a functional imaging technique which allows characterization of 
metabolic active tissues by demonstration of elevated FDG-uptake in these tissues (figure 2). 
Last decade the use of FDG-PET has shown impressive results in detection and staging of 
several lymphoma subtypes, especially aggressive lymphomas. Besides FDG-PET can be 
used for response evaluation and follow up. However, as PET scan lacks anatomic detail 
due to its poor resolution, a combined approach of PET and CT has been developed for both 
staging and response assessment purposes. Till now, experience with PET with or without 
CT imaging in PTLD has been limited to rather small retrospective single center experiences. 
Taken together these reports reveal that PET scan may have a high sensitivity for the 
detection of PTLD lesions, although PET scan has shown a low accuracy in low grade 
lymphomas and is not the preferred examination in case of suspicion of central nervous 
system (CNS) localization. In the latter situation MRI of the brain and cytological 
examination of cerebrospinal fluid should be performed.   
 
Stage I  Involvement of a single lymph node region (I) or one extralymphatic site (IE).  
Stage II  Involvement of two or more lymph node regions, at the same side of the 
diaphragm (II) or local extralymphatic extension plus one or more lymph node 
regions at the same side of the diaphragm (IIE).  
Stage III  Involvement of lymph node regions on both sides of diaphragm (III) which 
may include the spleen (IIIS) or accompanied by local extralymphatic extension 
(IIIE) or both (IIIES). 
Stage IV  Diffuse or disseminated involvement of one or more extralymphatic organs or 
sites, with or without associated lymphatic involvement.  
Each stage number is followed by either A (absence of B-symptoms) or B (presence of B-symptoms:  
unexplained weight loss > 10% baseline during 6 months before, unexplained fever > 38°C, night sweats). 
Table 3. Ann Arbor staging system for lymphoproliferative disorders 
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Fig. 2. Role of PET scan in staging and follow up 
A. Heart transplant recipient diagnosed with PTLD subtype DLBCL. Pet scan shows 
lymphoma localisation left axilla, lung bilateral and small intestine. This scan illustrates the 
increased incidence of organ involvement in PTLD compared to findings in lymphoma in 
immunocompetent patients. B. PET scan shows a complete metabolic remission following 
reduction of immunosuppression and four administrations of rituximab (Courtesy to Dr 
Lieselot Brepoels). 
9. Prevention 
The often very aggressive presentation and the poor prognosis of PTLD has led to an 
increased interest in adequate prevention of the disorder. At this moment many centers, 
similar to the intensive viral monitoring following allogeneic stem cell transplantation,  
advocate the use of EBV viral load monitoring as a tool to initiate pre-emptive therapy in 
case of rapid increase of the viral load. Classical EBV serology (anti-Viral Capsid Antigen 
[VCA] IgM and IgG, EBV-EA and EBNA) is not reliable in patients with a dysfunctional 
immune system, in particular transplant recipients.89 In this patient population viral load 
measurement by quantitative polymerase chain reaction (PCR) is a much more reliable test. 
During the last decades many authors have reported their experience with serial EBV viral 
load monitoring, both in adult and pediatric solid organ transplant recipients (as reviewed 
in ref 90 and 91).90,91 Although these series confirm the utility of serial monitoring in 
prevention of PTLD, the results need to be analyzed with caution.  
Firstly, most results are derived from retrospective single center studies, often mixing 
different populations.  
Secondly, there is a huge heterogeneity in methods, cut off values and source of samples 
(whole blood versus plasma versus peripheral blood mononuclear cells). In a prospective 
single center study Tsai et al compared PCRs with different gene targets (EBNA, EBER and 
LMP) and different sample sources (plasma and lymphocytes) in lung transplant patients. 
Free plasma EBNA PCR showed the highest specificity and positive predictive value, 
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making this test useful in identification and monitoring of patients with EBV-related PTLD. 
However,  the whole PCR panel was needed to rule out the presence of EBV-related PTLD.92  
Finally, pre-emptive decisions are very variable between different centers, ranging from 
more intensive monitoring to reduction of immunosuppression and antiviral therapy to 
monoclonal anti-CD20 therapy.  
In order to improve positive predictive value of EBV viremia, some authors propose to 
combine EBV PCR with measurements of T cell immunity like absolute lymphocyte count 
(<300/mm³) or the absence of EBV-specific CD8-positive cytotoxic T cells. However, these 
combinations have not been validated in larger series yet.93,94  Another approach may be the 
combination of EBV viral load and use of cytokine polymorphisms, as shown in a study in 
pediatric liver transplant recipients.95 
In addition other, but less used, preventive tools include incorporation of cytokine 
measurements. Elevated Interleukin-6 (IL-6) levels have been associated with the occurrence 
of PTLD following solid organ transplantation, whereas a strong correlation has been found 
between IL-10 and EBV viral load.96,97  
10. Treatment 
As development of PTLD is the consequence of an imbalance between immunosuppression 
and immunosurveillance, different approaches can be made in the treatment of the disorder. 
These approaches include improving reconstitution of the immune system, targeting the 
uncontrolled proliferation of malignant B cells and decreasing (EBV) viral load.98  
Unfortunately treatment for PTLD is largely based on retrospective data with only few 
prospective and no randomized trials being performed till now. As a consequence formal 
recommendations are lacking and currently treatment is largely physician or transplant 
center dependent. 
Taking into account that PTLD is always associated with a high degree of 
overimmunosuppression, the most important therapeutic intervention seems to be 
reduction of immunosuppression, leading to (partial) cellular (EBV specific) immunity 
reconstitution. However, in many cases this is insufficient and further therapy is needed. 
The spectrum of therapeutic options, including antiviral therapy, cytokines and 
chemotherapy, recently has been expanded with the use of monoclonal anti-B cell antibodies 
and EBV specific immunotherapy. In this chapter we will review the different currently 
used and future therapeutic options.     
10.1 Restoration of the immune system 
10.1.1 Reduction of immunosuppression 
Reduction of immunosuppression (RIS) has been considered standard therapy in PTLD 
following kidney (and other types) transplantation allowing reconstitution of the immune 
system, in particular EBV-specific cytotoxic lymphocyte response.99  Although no consensus 
has been reached, most transplant physicians agree to stop antimetabolites, reduce the 
calcineurin inhibitor dose with 50% and continue treatment with steroids.100 It seems 
appropriate to re-evaluate two to four weeks following initiation of RIS, if the clinical 
situation doesn’t oblige urgent treatment. Response rates to RIS alone in PTLD have a very 
wide variation ranging from almost no response to response rates exceeding 50%. This 
heterogeneity reflects the lack of standardization with respect to duration of RIS before re-
evaluation, response criteria and reduction regimen. Reshef et al recently published their 
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experience with RIS alone in 67 solid organ transplant recipients diagnosed with PTLD. 
Overall response rate was 45%, including 37% complete responses. The authors conclude 
that RIS alone might be a useful therapy in low risk PTLD patients as  the presence of bulky 
disease (> 7cm), advanced stage (Ann Arbor III-IV) and higher age (> 50 year) were 
independently associated with lack of response to RIS.101 In  a recent prospective trial 
however, examining the use of sequential RIS, interferon-┙-2B and chemotherapy in 16 
PTLD patients following SOT, RIS was associated with an overall response rate of 6% 
without any complete remission, even though acute graft rejection was seen in one third of 
the patients. Half of the patients showed progressive disease during the period of RIS.102  
The main problem associated with RIS is rejection of the allograft. In contrast to heart- and 
lung transplantation kidney recipients can still be rescued by hemodialysis, explaining the 
tendency for more aggressive RIS in kidney transplantation compared to other types of 
organ transplantation. Whether immunosuppressive therapy can be safely reduced during 
chemotherapy was recently addressed in a retrospective analysis of 58 kidney transplant 
recipients. A significant improvement in renal function was observed in patients treated 
with RIS followed by CHOP chemotherapy with or without rituximab, reflecting the 
immunosuppressive properties of chemotherapy.103 However, the question whether 
immunosuppression can be disrupted completely during chemotherapy remains 
unanswered. Even if immunosuppression is discontinued during chemotherapy, a reduced 
dose is re-initiated after termination of the chemotherapy in most centers.   
Proliferation signaling inhibitors (PSI) or mammalian target of rapamycin (mTOR) inhibitors 
(sirolimus, everolimus)  possess a unique combination of both immunosuppressive and anti-
proliferative properties. From a theoretical point of view they may show superiority in the 
treatment of malignancies in transplant recipients, which was confirmed in small single 
center trials.28,104 However, as stated before,  maintenance therapy with PSI might be 
associated with increased risk for PTLD.31,32      
10.1.2 Adoptive immunotherapy  
The use of EBV specific cytotoxic lymphocytes (CTLs) is another attractive option to induce  
EBV specific cellular immune response.65,68 This type of adoptive immunotherapy was first 
described in the early 1990s in patients with EBV related PTLD following hematopoietic 
stem cell transplantation. In contrast to PTLD following SOT, in which the disorder mostly 
arises in recipient lymphocytes,  hematopoietic stem cell related PTLD mostly derives from 
donor cells. In this way donor lymphocyte infusions were given to evoke an EBV-specific 
response. Despite impressive response rates, a high incidence of graft versus host disease 
was observed.105,106  Due to this strong alloreactive mediated complications, further attempts 
were made to isolate expanded EBV-specific CTLs. By infusing these CTLs, both autologous 
(recipient derived PTLD) and allogeneic (isolated from the donor itself or from a bank of 
partial HLA-matched voluntary donors), promising results were obtained in PTLD patients 
after SOT, recently reviewed by Merlo et al.107 However, wide applicability has been limited 
so far because of pronounced labor-intensive procedure and by availability problems.    
10.1.3 Cytokine therapy 
Interferon-alpha (IFN-┙) is a cytokine with well known anti-viral and anti-neoplastic 
properties.108 In the late 90s several case reports and small case series have been published 
showing effectiveness of cytokine therapy in the treatment of PTLD. Davis et al treated 16 
newly diagnosed patients with subcutaneous IFN-┙, leading to a complete response rate of 
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50%. However treatment was associated with a high rate of graft rejection and was poorly 
tolerated.109 However, in their recent report on the use of sequential RIS, IFN-┙-2B and 
chemotherapy in PTLD Swinnen et al observed a lower overall response rate of 30% with 
only 15% patients with complete remission.102 
10.2 Anti- B cell therapy 
10.2.1 Cytokine therapy 
Interleukin-6 (IL-6) is a cytokine produced by monocytes, fibroblasts and endothelial cells, 
promoting the growth of EBV-immortalized cells in vitro. In the early 90s Tosato et al 
demonstrated elevated serum IL-6 levels in patients with PTLD, pointing to a possible role 
in the pathogenesis of the disorder and providing an opportunity for new therapeutic 
modalities.110  In a multicentric phase I-II trial assessing the role of anti-IL-6 monoclonal 
antibodies in non-responders to RIS 8 out of 12 patients responded without major side 
effects.111 Although cytokine therapy clearly showed promising results in the treatment of 
PTLD, currently its use has been largely replaced by monoclonal anti-CD20 therapy.  
10.2.2 Surgery and radiotherapy 
The role of surgery and radiotherapy in the treatment of PTLD is limited to localized disease, 
especially in early type PTLD and mostly combined with RIS. Besides these treatment options 
can be used in case of local complications like bleeding, pain and compression. 71,99,112,113  In 
primary central nervous system (PCNSL) PTLD, radiotherapy and chemotherapy may both 
lead to a high response rate.72,114,115  Although rituximab hardly crosses the blood-brain-barrier 
(BBB), case reports have shown promising results with the use of systemic rituximab in the 
treatment of  PCNSL-PTLD, probably due to disruption of the BBB in patients presenting with 
central nervous system malignancies. However, the exact value of systemic or intrathecal 
rituximab needs to be determined taking into consideration the fact that in most cases anti-
CD20 therapy was combined with other treatments.116,117      
10.2.3 Chemotherapy 
In most lymphoproliferative disorders in immunocompetent patients chemotherapy 
remains the cornerstone of therapy, often combined with lymphoma-specific 
immunotherapy. As a consequence chemotherapy (mostly CHOP or a CHOP-like regimen) 
has been considered for many years standard therapy in PTLD not responding to RIS. 
However, due to the immunocompromised state of the patient treatment related mortality, 
especially infectious, is substantially higher in this population, even though the use of broad 
spectrum antibiotics  and G-CSF clearly has reduced the complication rate of 
chemotherapy.118-120 Till now only one uncontrolled prospective trial has been published 
reporting the effectiveness of low dose chemotherapy in pediatric PTLD patients,  leading to 
an overall response rate of 83% and a 2-year overall survival rate of 73%.121 In adults all 
currently available evidence regarding the use of chemotherapy is based on retrospective 
data.122 In an  analysis of the Israel Penn International Transplant Tumor Registry outcome 
with different chemotherapy schedules were compared. Treatment with CHOP 
chemotherapy was associated with a 5 year overall survival of 24% with a PTLD-specific 
mortality of 34%, whereas single agent chemotherapy appeared to be inferior compared to 
combination chemotherapy.118  One other approach may be sequential therapy using RIS, 
interferon-┙ and systemic chemotherapy, leading to lower tumor burden before start of 
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chemotherapy. This approach showed promising results in two prospective trials.102,109 
However, as described below, results and especially tolerance may be improved by 
substituting IFN-┙ by anti-CD20 monoclonal therapy.  
Taken together we can conclude that, despite high initial response rates using chemotherapy 
after failing of RIS,  toxicity and long term outcome remain problematic. However, in case of 
aggressive presentation of high grade lymphomas, including plasmablastic NHL, Burkitt 
and Burkitt-like NHL and T-cell NHL, and in case of Hodgkin or Hodgkin-like  
lymphoma, for which no immunotherapy is available, upfront chemotherapy needs to be 
considered.  
10.2.4 Monoclonal anti-B cell therapy 
During the last decade monoclonal anti-B-cell antibodies have emerged as a powerful 
treatment modality in most B-cell lymphoproliferative disorders, both indolent and 
aggressive. Consequently this new kind of immunotherapy was also investigated in the 
treatment of PTLD, most of which express CD20. Before the advent of rituximab 
combination of murine anti-CD21 and anti-CD24 monoclonal antibodies showed 
encouraging results in B-PTLD.123  Most experience however has been obtained with 
rituximab, a chimeric murine/human anti-CD20 antibody, with numerous case reports, case 
series and larger retrospective analyses found in the international literature.122 Besides  five 
prospective trials have been published till now assessing the role of rituximab in PTLD, 
showing overall response rates ranging between 44% and 64%.124-128 Most patients were 
treated with the standard rituximab dose of 375 mg/m²/week during 4 consecutive weeks, 
although Gonzalez-Barca et al introduced the concept of risk adapted extended treatment 
with rituximab in case of partial response following 4 weekly admissions. With this 
approach the number of complete responders was upgraded from 34% after 4 admissions to 
60.5% following 8 doses.127    
Although treatment with rituximab is associated with a high response rate in PTLD, it is 
important to keep in mind that it does not improve (virus-specific) cellular immunity 
necessitating the need for simultaneous RIS.129 Conversely, severe B-cell depletion due to 
treatment with rituximab was not associated with diminished EBV-specific T-cell immunity 
in non-transplanted patients presenting with lymphoproliferative disorders.130  
Although toxicity of rituximab seems to be rather low in the different retrospective and 
prospective trials, caution is warranted based on recently described infectious complications 
in non-transplant related lymphoproliferatieve disorders, including progressive multifocal 
leucoencephalopathy and hepatitis B reactivation.131,132  
10.3 Anti- EBV therapy 
10.3.1 Antiviral therapy  
As the majority of PTLD cases are associated with EBV related lymphocyte proliferation,  
the use of antiviral treatment was already explored almost thirty years ago.133 The efficacy of 
classical antiviral drugs in the treatment of PTLD however has been very controversial. 
Nucleoside analogues, including aciclovir and ganciclovir, inhibiting replication of many 
herpes viruses, have shown in vitro and in vivo resistance against EBV related malignancies 
as most of these tumors do not express viral thymidine kinase (TK). Some case reports or 
small series have shown limited curative potential of these antiviral agents134, which could 
be explained by some degree of lytic replication in PTLD although the effect of other 
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simultaneous interventions might have influenced the responses. In the above mentioned 
study on the use of sequential RIS, interferon-┙-2B and chemotherapy, all 16 patients 
received intravenous acyclovir during the period of RIS, without any response.102  Of 
interest,  prophylactic treatment with nucleoside analogues during three months following 
heart transplantation was associated with reduced PTLD risk in the Spanish registry.135,136  
This effect was also observed in a multicentric case-control study of kidney transplant 
recipients. The authors showed that antiviral prophylactic treatment was associated with a 
significant decrease in the risk of PTLD, especially in the first year posttransplant.137  
Experience with other antiviral agents like foscarnet and cidofovir, which act independently 
of the viral TK, is very limited. Oertel et al reported on their experience with foscarnet in 
three patients. All three patients achieved a complete remission, correlating with the 
expression of BZLF1/ZEBRA protein, which is an early antigen of lytic EBV activity.138  
10.3.2 Intravenous immune globulins 
The use of intravenous immune globulins (IVIG)  might be another attractive  therapy in 
PTLD, based on the presence of antibodies against EBV proteins. However, literature is 
limited to some isolated case reports in which IVIG is combined with different other 
therapies.139 There is some more data available regarding IVIG prophylaxis following 
transplantation, though the results are very conflicting. Opelz et al examined the effect of 
anti-CMV prophylaxis on the occurrence of PTLD in a large registry study. The first year 
following kidney transplantation no case of PTLD was seen in patients who received anti-
CMV IVIG compared to patients with antiviral agents or without prophylaxis. After the first 
year this difference disappeared. The authors conclude that anti-CMV IVIG might posses a 
broad range of anti-EBV activity.140 On the other hand Green et al performed a randomized 
controlled trial in pediatric liver transplant patients, revealing no significant effect of the use 
of anti-CMV IVIG on occurrence of PTLD.141 As a consequence it remains a matter of debate 
whether IVIG should be incorporated early in transplant programs. 
10.3.3 Arginine butyrate 
Recently very promising results have been described treating fifteen refractory EBV related 
malignancies –including 6 PTLDs- with arginine butyrate, resulting in pharmacological 
induction of viral TK. As this approach makes the tumor sensitive to treatment with 
nucleoside analogues, ganciclovir is added. With this combination therapy  an overall 
response rate of 83% was observed in the PTLD subgroup with an acceptable toxicity 
profile.142 
10.4 Retransplantation 
In patients successfully treated for PTLD, but with loss of their graft due to reduced 
immunosuppression, retransplantation may be feasible. Birkeland et al reported on 5 kidney 
transplant recipients who underwent retransplantation without any sign of disease 
recurrence up to three years after transplantation.143 In another small series Karras et al 
described six other cases without disease recurrence with a median posttransplant follow up 
of 30 months.144 The largest published series was based on the OPTN/UNOS database, in 
which 69 patients with a history of PTLD underwent retransplantation. Time from PTLD to 
retransplantation ranged from < 1 year to 5-10 years. Immunosuppressive therapy was very 
similar to regimens used after first transplants. Patient and graft survival was very good, 
although outcome seemed to be better in abdominal organ retransplantation.145 
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11. Prognosis 
In general the prognosis of PTLD is poor compared to ‘similar’ lymphoproliferative 
disorders in immune competent patients. In kidney transplant recipients 5 year overall 
survival following diagnosis of PTLD ranges from 40% to 60%, with the lowest survival 
rates in patients presenting with CNS involvement.10,73 
Although several prognostic scores have been proposed by different authors, validation of 
this scores in different transplant populations have not been done or have shown conflicting 
results, partially due to heterogeneity in patient population and treatment.74,128,146-149  
However poor prognostic factors in immunocompetent lymphoma patients, including 
higher age, advanced disease, poor performance state and elevated lactate dehydrogenase, 
have also shown their value in outcome prediction of PTLD patients. Table 4 gives an  
 
Score Population 
Number 
of 
patients 
Treatment Risk factors 
International 
Prognostic 
Index (IPI)146 
Immunocompetent 
patients with 
aggressive NHL 
2031 
Anthracyclin 
based 
combination 
chemotherapy 
age,  LDH, stage, 
performance 
state, number of 
extranodal sites 
Leblond147 SOT 61 Heterogenous 
Performance 
state, number of 
involved sites 
Ghobrial148 SOT 107 Heterogenous 
Performance 
state, 
monomorphic 
subtype, graft 
involvement 
Choquet128 SOT 60 Heterogenous 
Age, performance 
state, LDH 
Hourighan149 Kidney 42 Heterogenous 
LDH, B-
symptoms 
Evens74 SOT 80 Heterogenous 
No rituximab 
therapy, CNS 
involvement, 
number of 
extranodal sites, 
albumin, bone 
marrow 
involvement 
Table 4. Prognostic scores in PTLD 
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overview of the different proposed prognostic scores. Cesarman et al reported a poor 
response to RIS in patients showing bcl-6 mutations.150 This finding, however, has not been 
examined in other studies. 
New and especially validation of prognostic factors, both clinical/biochemical and 
molecular, may lead to better risk stratification in PTLD.  
12. Future 
Although we have learned a lot about all different aspects on PTLD during the last decades, 
even more questions remain. Further research and clinical studies are needed in this rapidly 
changing field with increasing transplant activities worldwide and the use of new and very 
potent immunosuppressive therapy.  
Table 5 summarizes our current knowledge of PTLD and defines future opportunities which 
can only be possible by close cooperation between all departments involved in transplant 
patient care (transplantation unit, clinical hematology/oncology, pathology, radiology, 
nuclear medicine, immunology and virology) and between the different transplant centers.  
 
Aspect Knowledge Future perspectives 
Incidence 2% 
Nationwide prospective and complete 
registry,… 
Risk factors 
Type of organ, EBV R-
/D+, intensity 
immunosuppression 
Measuring ‘overall immune suppression’, 
further search for specific role of 
immunosuppressive agents,… 
Pathogenesis 80-85% EBV related 
Role of other viruses, molecular pathways 
(gene expression profiling, single nucleotide 
polymorphism analysis, comparative 
genome hybridisation arrays,…),… 
Diagnosis Biopsy, WHO 2008 
Non-invasive diagnosis? Role of PET/CT 
scan, role of magnetic resonance imaging,… 
Staging 
CT scan, bone marrow 
examination 
Role of PET/CT scan, role of magnetic 
resonance imaging,… 
Prevention 
Serial monitoring EBV 
PCR? 
Standardisation of EBV PCR, determination 
cut off value, role of HLA, cytokine gene 
polymorphisms,… 
Therapy Heterogenous 
Prospective studies, international working 
group consensus,… 
Prognosis Poor 
Identification of new (clinical and non-
clinical) prognostic markers, prospective 
validation of prognostic scores,… 
Table 5. Current knowledge and future perspectives in PTLD 
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There are many obstacles in kidney transplantation. For the transplant team, there is the balance between
immunosuppression to aid in the recipientâ€™s tolerance of the allograft and the infection risk of a suppressed
immune system. These potential long term complications of kidney transplantation are relatively well known,
but there are many other complications that patients and families do not consider when preparing themselves
for a kidney transplant. Although the benefits of attempting a kidney transplant far outweigh downfalls of the
long term sequelae, kidney transplantation is by no means a benign procedure. It is the hope of these authors
that the reader will leave with a sense of understanding towards the kidney recipients.
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